India’s drug regulator has granted emergency use authorisation (EUA) for Biological E’s COVID-19 vaccine Corbevax for children aged five to 12 years and Bharat Biotech’s Covaxin for those in the age group of six to 12 years, Union Health Minister Mansukh Mandaviya said on Tuesday.

The Drugs Controller General of India (DCGI) has also granted the EUA to Cadila for its ZyCoV-D for an additional dose of 3mg with a two-jab inoculation schedule 28 days apart for those aged above 12 years. ZyCoV-D is currently approved for a 2mg three-dose vaccination schedule. The approval by the DCGI comes following recommendations by the Subject Expert Committee on COVID-19 of the Central Drugs Standard Control Organisation.